Barnes Group (B)
(Delayed Data from NYSE)
$40.61 USD
-0.16 (-0.39%)
Updated May 16, 2024 03:59 PM ET
After-Market: $40.63 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
B 40.61 -0.16(-0.39%)
Will B be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for B based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for B
Don't Overlook Barnes Group (B) International Revenue Trends While Assessing the Stock
Barnes Group (B) Q1 Earnings & Revenues Surpass Estimates
B: What are Zacks experts saying now?
Zacks Private Portfolio Services
Barnes Group (B) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Barnes Group (B) Q1 Earnings and Revenues Top Estimates
Analysts Estimate Barnes Group (B) to Report a Decline in Earnings: What to Look Out for
Other News for B
Barnes Group Reaches Analyst Target Price
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
(B) - Analyzing Barnes Gr's Short Interest
Barnes Group: A Promising Turnaround With An Aerospace Focus